Compare Ishares Msci Brazil ETF (EWZ) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs Eli Lilly And Co — how do they compare? Ishares Msci Brazil ETF trades at $43.01 (market cap $11.30B), while Eli Lilly And Co trades at $1,169.5 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 92× Ishares Msci Brazil ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while Ishares Msci Brazil ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Brazil ETF for 50 Days and Eli Lilly And Co for 93 Days on average.
| EWZ | LLY | |
|---|---|---|
Market Cap | $11.30B | $1.04T |
Volume | 44,036,597 | 3,064,878 |
Sector | Broad Market / Factor | Health |
52-Week High | $43.00 | $1.28K |
52-Week Low | $28.79 | $799.57 |
Typical Hold Time | 50 Days | 93 Days |
Enterprise Value | — | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, trades at $42.37, down 1.47% today. The technical outlook is mixed with moving averages signaling bullish momentum but oscillators showing bearish pressure, including overbought RSI readings. Recent news highlights significant investor focus on Brazil's upcoming October election, with unusual options activity and institutional positioning suggesting anticipation of market-moving outcomes. The ETF serves as a key diversifier for U.S. investors seeking exposure to Brazilian equities and commodities.
The outlook for EWZ is heavily tied to Brazilian political and economic developments, particularly the election outcome. While technical indicators show conflicting signals, the substantial options volume and institutional interest indicate heightened expectations for volatility. Key risks include election uncertainty and U.S.-Brazil trade tensions, but potential rate cuts and commodity exposure offer upside for diversified portfolios.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% today, reflecting strong momentum driven by robust earnings beats and bullish technical signals. The stock exhibits impressive fundamentals with 2025 revenue of $65.18B and net income of $20.64B, yielding a net margin of 31.66%. Recent news highlights promising pipeline developments in weight-loss drugs, including EloraTZP, which outperformed Zepbound in trials, reinforcing its competitive edge in the obesity and diabetes markets.
Outlook remains positive given analyst consensus of a $1,350 price target and 73% buy ratings, though high valuation multiples (P/E 39.26) and rising debt-to-asset ratios (42.78% in 2024) warrant caution. Key risks include regulatory hurdles and intensifying competition from rivals like Novo Nordisk, but Lilly's innovation pipeline and market leadership position it for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
